SW
TCRT icon

SVB Wealth’s Alaunos Therapeutics TCRT Stock Holding History

SVB Wealth’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-67
Closed -$83K – 537
2015
Q4 		$83K Buy
+67
New +$111K ﹤0.01% 523
2015
Q3 		– Sell
-67
Closed -$120K – 578
2015
Q2 		$120K Buy
+67
New +$104K ﹤0.01% 542

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SVB Wealth's TCRT Position: Q1 2016 in Review

SVB Wealth sold out of Alaunos Therapeutics (TCRT) in Q1 2016, closing a stake of 67 shares — an estimated $83K sold.

SVB Wealth first reported a position in TCRT in Q2 2015 and held it in 2 quarters. The position peaked at $120K in Q2 2015. 143 funds tracked by Wall St. Rank hold TCRT as of Q1 2016.

  • SVB Wealth reported no remaining Alaunos Therapeutics position as of Q1 2016 after selling out during the quarter.
  • SVB Wealth sold 67 Alaunos Therapeutics shares in Q1 2016, an estimated $83K.
  • SVB Wealth first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 2 quarters.
  • SVB Wealth's Alaunos Therapeutics position peaked at $120K in Q2 2015.
  • 143 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2016.

Based on SVB Wealth's 13F filing for Q1 2016, filed 13 May 2016.